Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ARDX by emailGet an email when ARDX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ARDX, unsubscribe in one click. Privacy
📣 What ARDX Says Is Next
by the end of 2026 · “The Company is on track to complete enrollment by the end of 2026 and to announce top-line data in the second half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
by the end of 2026 · “The Company expects to complete enrollment by the end of 2026 with topline data read out in the second half of 2027.”
Company press release, Apr 30, 2026 · SEC filing
by the end of 2026 · “Enrollment in ACCEL is expected to be completed by the end of 2026 and topline readout is expected in the second half of 2027.”
Company press release, Feb 19, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ARDX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARDX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.